How Do PD-1/PD-L1 Inhibitors Exert Antitumor Effects?

Against the backdrop of increasingly precise and individualized cancer treatment, immunotherapy has emerged as a major breakthrough reshaping the clinical landscape. Among these advances, PD-1/PD-L1 inhibitors are now widely used across multiple solid tumors and hematologic malignancies.

Understanding their mechanisms helps optimize treatment strategies and supports the development of combination therapies in modern oncology.

---

1. Immune Escape Mechanism: Why Tumors Evade the Immune System

Under normal conditions, the immune system identifies and eliminates abnormal cells through T-cell–mediated responses. However, tumor cells can suppress immune activity through immune checkpoint pathways.

A key mechanism involves:

• PD-1 receptors on T cells
• PD-L1 expression on tumor or antigen-presenting cells

When PD-1 binds to PD-L1:

• T-cell proliferation decreases
• Cytotoxic activity is suppressed
• T-cell exhaustion may occur

This allows tumor cells to survive and continue growing despite immune surveillance.

---

2. Mechanism of PD-1/PD-L1 Inhibitors

PD-1/PD-L1 inhibitors are monoclonal antibodies that block this inhibitory interaction.

For example, clinically used PD-1 antibodies such as
👉 Penpulimab (Anniko)
bind to the PD-1 receptor and prevent interaction with PD-L1, thereby restoring immune activity. :contentReference[oaicite:0]{index=0}

Core actions:

• Block PD-1 receptor signaling
• Prevent PD-L1 binding to T cells

Key effect:

👉 Reactivate suppressed T cells
👉 Restore immune-mediated tumor killing

Unlike chemotherapy, these drugs do not directly kill cancer cells, but instead enhance the body’s own immune response.

---

3. Remodeling the Tumor Microenvironment

Blocking PD-1/PD-L1 does more than activate T cells — it reshapes the entire tumor immune environment.

Effects include:

• Increased cytokine release
• Enhanced immune cell infiltration
• Improved tumor antigen exposure

This creates a positive immune feedback loop.

Additionally, immune checkpoint inhibitors may also influence immunosuppressive components such as regulatory T cells and myeloid-derived suppressor cells.

---

4. Clinical Application: From Monotherapy to Combination Therapy

PD-1/PD-L1 inhibitors are now widely applied in:

• Non-small cell lung cancer (NSCLC)
• Melanoma
• Cervical cancer

For instance,
👉 Enlonstobart (Enshuxing)
is a PD-1 inhibitor approved for PD-L1–positive cervical cancer, demonstrating how immune checkpoint blockade is used in real-world oncology treatment. :contentReference[oaicite:1]{index=1}

Evolution of use:

• Initially: late-line monotherapy
• Now: frontline combination therapy

Combination strategies may include chemotherapy, radiotherapy, or targeted therapy.

---

5. Mechanism Extension: Link to RNA-Based Therapies

While PD-1/PD-L1 inhibitors regulate immune checkpoints, newer therapies operate at the gene expression level.

For example,
👉 RNA interference therapy (Vutrisiran)
works by silencing disease-related mRNA, representing a different but complementary therapeutic strategy. :contentReference[oaicite:2]{index=2}

This highlights a broader trend:

👉 modern medicine is shifting from protein-level targeting → gene-level regulation

---

6. Safety and Immune-Related Adverse Events

Because these drugs activate the immune system, they may also trigger immune-related adverse events (irAEs).

Common risks:

• Skin reactions
• Thyroid dysfunction
• Hepatitis
• Pneumonitis

These effects result from immune-mediated damage to normal tissues rather than direct toxicity.

👉 Clinical management requires:

• Continuous monitoring
• Early intervention
• Individualized treatment strategies

---

7. Conclusion

PD-1/PD-L1 inhibitors represent a paradigm shift in oncology by:

• Blocking immune checkpoint pathways
• Restoring T-cell function
• Reshaping the tumor microenvironment

From agents like
👉 Penpulimab (Anniko)

to emerging RNA-based approaches, modern oncology is evolving toward more precise and system-level treatment strategies.

As biomarker research and combination therapies continue to advance, immunotherapy will remain a central pillar of precision medicine.

---